Cargando…
Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States
OBJECTIVE: To understand factors guiding overactive bladder (OAB) therapy selection and experience with combination therapy (antimuscarinics and beta-3 agonists). METHODS: Cross-sectional surveys of OAB patients and OAB-treating physicians in the USA were conducted. Patients receiving monotherapy wi...
Autores principales: | Kraus, Stephen R., Li, Junlong, Kristy, Rita M., Lockefeer, Amy, Yang, Hongbo, Zhou, Mo, Walker, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127871/ https://www.ncbi.nlm.nih.gov/pubmed/35588263 http://dx.doi.org/10.1177/03000605221098176 |
Ejemplares similares
-
Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022) -
A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA
por: Campbell, Noll L., et al.
Publicado: (2021) -
Overactive bladder in an integrated delivery system: a longitudinal cohort study
por: Linder, Jeffrey A., et al.
Publicado: (2020) -
Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015) -
Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis
por: Lozano-Ortega, Greta, et al.
Publicado: (2020)